Clinical-Stage Companies / Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

Pre-Approval PRO BETA

Total Trials

Phase 3

Phase 2

Recruiting

166

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Non-small Cell Lung Cancer Breast Cancer SCLC Prostate Cancer Small Cell Lung Cancer

Clinical Trials (7)

NCT05987956 Phase 2 ACTIVE NOT RECRUITING

Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Started: 3/18/2026

NCT06062810 Phase 2 ACTIVE NOT RECRUITING

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Started: 6/21/2025

NCT07145333 Phase 2 ACTIVE NOT RECRUITING

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

Started: 8/12/2025

NCT03348670 Phase 2 ACTIVE NOT RECRUITING

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

Started: 8/18/2023

NCT01064466 Phase 2 ACTIVE NOT RECRUITING

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

Started: 7/16/2025

NCT07033585 Phase 2 ACTIVE NOT RECRUITING

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Started: 6/15/2025

NCT02403505 Phase 1 ACTIVE NOT RECRUITING

Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer

Started: 12/28/2021

Drug Candidates

Alectinib - Usual Alectinib - Study Raloxifene - Usual Raloxifene - Study Topotecan - usual Topotecan - study Abiraterone - Usual Abiraterone - Study ETOPOSIDE - Usual ETOPOSIDE - Study

Activity Status: Active

Last Trial Started: 3/18/2026

Last Trial Ended: N/A

Trials (12 months): 5

Completed Trials: 0

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.